Profil bibliographique

Claire Watkins

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

64Publications signalées

15650Citations signalées

0Affiliations récentes

Domaines associés

Lung Cancer Treatments and MutationsAdvanced Breast Cancer TherapiesLipoproteins and Cardiovascular HealthLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

Publications récentes

Accès ouvert 2025 letterOpenAlex

Comment on: “Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E‑Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations”

Claire Watkins, Josep M. Piulats

1 citationClinical Drug Investigation

Accès ouvert 2025 articleOpenAlex

Further Practical Guidance on Adjusting Time‐To‐Event Outcomes for Treatment Switching

Claire Watkins, Eva Kleine, Miguel A. Miranda, Emmanuel Bourmaud et autres

6 citationsPharmaceutical Statistics

Accès ouvert 2024 reviewOpenAlex

CO92 Comparative Efficacy and Safety of Faricimab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion (RVO): A Systematic Literature Review and Network Meta-Analysis

C Bührer, Claire Watkins, M Bagijn, Osvaldo Cox et autres

0 citationsValue in Health

Accès ouvert 2024 erratumOpenAlex

Correction to: Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis

Claire Watkins, Tatiana Paulo, C Bührer, Nancy M. Holekamp et autres

3 citationsAdvances in Therapy

Accès ouvert 2023 articleOpenAlex

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Josep M. Piulats, Claire Watkins, Marcel Costa-García, L. Del Carpio et autres

45 citationsAnnals of Oncology

Accès ouvert 2023 articleOpenAlex

Intravenous Vitamin C for Patients Hospitalized With COVID-19

Simin Aysel Florescu, Dragos Stanciu, Mihaela Zaharia, Alma Kosa et autres

51 citationsJAMA

Accès ouvert 2023 reviewOpenAlex

Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis

Claire Watkins, Tatiana Paulo, C Bührer, Nancy M. Holekamp et autres

43 citationsAdvances in Therapy

Accès ouvert 2023 articleOpenAlex

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19

Simin Aysel Florescu, Dragos Stanciu, Mihaela Zaharia, Alma Kosa et autres

68 citationsJAMA

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Data from Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

Massimo Cristofanilli, Vicente Valero, Aroop Mangalik, Melanie Royce et autres

0 citations

Accès ouvert 2023 otherOpenAlex

Data from Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

Massimo Cristofanilli, Vicente Valero, Aroop Mangalik, Melanie Royce et autres

0 citations

Accès ouvert 2023 otherOpenAlex

Data from Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

Massimo Cristofanilli, Vicente Valero, Aroop Mangalik, Melanie Royce et autres

0 citations

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Data from Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

Massimo Cristofanilli, Vicente Valero, Aroop Mangalik, Melanie Royce et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.